New insider activity at Xeris Pharmaceuticals ( (XERS) ) has taken place on March 22, 2025.
Director Beth Hecht recently sold 40,000 shares of Xeris Pharmaceuticals stock, generating a total of $217,200 from the transaction.
Recent Updates on XERS stock
In the last 24 hours, Xeris Pharmaceuticals has seen significant developments that have influenced its stock price. The company announced FDA approval for its Gvoke VialDx as a diagnostic aid, which is expected to enhance its market presence. Additionally, Xeris has partnered with American Regent for the commercialization of this product in the U.S. Analysts have responded positively to Xeris’ recent earnings call, which highlighted record-breaking revenues and a positive adjusted EBITDA for the first time. The company’s strong guidance for 2025, projecting over 30% revenue growth, has led to increased price targets from several firms. Leerink, Craig-Hallum, and Piper Sandler all raised their price targets, citing the company’s robust Q4 results, strong 2025 guidance, and the exceptional performance of products like Recorlev and Gvoke as key reasons for their optimism.
More about Xeris Pharmaceuticals
YTD Price Performance: 59.25%
Average Trading Volume: 2,190,679
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $803.6M